BPI-23314 / Betta Pharma - LARVOL DELTA

Phase 1 study of BPI-23314, a novel BET inhibitor and degrader, in advanced myeloid leukemia (AML) (AACR 2024) - "BPI-23314 monotherapy exhibited preliminary clinical efficacy with manageable adverse events in patients with R/R AML. The study is ongoing. The satisfactory pharmacokinetic attribute and outstanding safety profile of BPI-23314 provide compelling rationales for further exploration of its therapeutic potential."

Metastases • P1 data • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology